Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia

Area of Science:

• Neurogenetics
• Parkinson's Disease Research
• Pharmacogenomics

Background:

• Levodopa-induced dyskinesia (LID) is a frequent complication of levodopa therapy for Parkinson's disease (PD).
• Genetic factors, including variants in GBA1 and LRRK2, and dopaminergic system dysfunction, are implicated in LID development.

Purpose of the Study:

• To investigate the impact of specific genetic variants on the risk and timing of LID development in PD patients.
• To analyze the association of GBA1 and LRRK2 variants with LID.
• To evaluate polygenic risk scores (PRS) related to PD and dopaminergic pathways for LID risk prediction.

Main Methods:

• Genome-wide association study (GWAS) and targeted analyses of GBA1 and LRRK2 variants.
• Calculation of polygenic risk scores (PRS) for PD and dopaminergic transmission.
• Logistic and Cox regression analyses in a cohort of 1612 PD patients with LID and 3175 without LID.

Main Results:

• GBA1 variants showed a significant association with increased LID risk (OR=1.65).
• LRRK2 variants were linked to a reduced time to LID onset (HR=1.42).
• Higher quartiles of PD and dopamine pathway PRS were associated with increased LID risk and reduced time to onset, respectively.

Conclusions:

• Genetic variants in PD-associated genes (GBA1, LRRK2) and dopaminergic pathways play a role in LID risk and progression.
• These genetic factors may inform future clinical strategies for managing LID in Parkinson's disease.
• Further research is warranted to translate these genetic insights into clinical practice.